![vTv Therapeutics](https://gocience.com/logos/new/5c5d2ad70c6eab50a29012cb4ebda5a7a7c3e459330bc2b6006bba165f66f99d.jpg)
V Tv Therapeutics
Pharmaceuticals, 4170 Mendenhall Oaks Pkwy, High Point, North Carolina, 27265, United States, 11-50 Employees
Phone Number: 33********
Who is VTV THERAPEUTICS
vTv is a clinical stage biotechnology company with a pipeline of drug candidates led by cadisegliatin (TTP399), a potentially transformative treatment for the reduction of hypoglycemic ep...
Read More
![map](/x-assets/maps1.0-950f22e3512fa69a51fdf6612dcb593a74c2f8790b6e4ec5601cebb82b592ab9.png)
-
Headquarters: 4170 Mendenhall Oaks Pkwy, High Point, North Carolina, 27265, United States
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from VTV THERAPEUTICS
vTv Therapeutics Org Chart and Mapping
Similar Companies to vTv Therapeutics
CinRx Pharma
-
11-50
-
$ 1 Million to 5 Million
Design Therapeutics
-
51-200
-
$ 10 Million to 25 Million
Longboard Pharmaceuticals
-
11-50
-
$ 10 Million to 25 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding VTv Therapeutics
Answer: vTv Therapeutics's headquarters are located at 4170 Mendenhall Oaks Pkwy, High Point, North Carolina, 27265, United States
Answer: vTv Therapeutics's phone number is 33********
Answer: vTv Therapeutics's official website is https://vtvtherapeutics.com
Answer: vTv Therapeutics's revenue is $25 Million to $50 Million
Answer: vTv Therapeutics's SIC: 2834
Answer: vTv Therapeutics's NAICS: 325412
Answer: vTv Therapeutics has 11-50 employees
Answer: vTv Therapeutics is in Pharmaceuticals
Answer: vTv Therapeutics top competitors include: CinRx Pharma , Design Therapeutics , Longboard Pharmaceuticals
Answer: vTv Therapeutics contact info: Phone number: 33******** Website: https://vtvtherapeutics.com
Answer: vTv is a clinical stage biotechnology company with a pipeline of drug candidates led by cadisegliatin (TTP399), a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month